News >

Expert Predicts Promising Regimens Ahead in MCL

Angelica Welch
Published: Saturday, Sep 15, 2018

Michael Wang, MD
Michael Wang, MD
The pipeline for relapsed/refractory mantle cell lymphoma (MCL) treatment is beginning to evolve with novel agents and combination regimens that have the potential to improve patient outcomes, said Michael Wang, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x